Improving function: a new treatment era for multiple sclerosis?
Thompson
Alan
A
Institute of Neurology, University College London, London WC1N 3BG, UK. A.Thompson@ion.ucl.ac.uk
Polman
Chris
C
D015761:4-Aminopyridine / Q000008:administration & dosage / Q000627:therapeutic use*; D000284:Administration, Oral; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy*; D026902:Potassium Channel Blockers / Q000008:administration & dosage / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016138:Walking
D003692:Delayed-Action Preparations; D026902:Potassium Channel Blockers; D015761:4-Aminopyridine